{"id":"NCT01160211","sponsor":"Novartis Pharmaceuticals","briefTitle":"A Study to Compare the Safety and Efficacy of an Aromatase Inhibitor in Combination With Lapatinib, Trastuzumab or Both for the Treatment of Hormone Receptor Positive, HER2+ Metastatic Breast Cancer","officialTitle":"A Phase III Trial to Compare the Safety and Efficacy of Lapatinib Plus Trastuzumab Plus an Aromatase Inhibitor (AI) vs. Trastuzumab Plus an AI vs. Lapatinib Plus an AI as 1st- or 2nd- Line Therapy in Postmenopausal Subjects With Hormone Receptor+, HER2-positive Metastatic Breast Cancer (MBC) Who Received Prior Trastuzumab and Endocrine Therapies","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2011-05-05","primaryCompletion":"2016-03-11","completion":"2022-06-06","firstPosted":"2010-07-12","resultsPosted":"2019-07-15","lastUpdate":"2025-03-07"},"enrollment":369,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Neoplasms, Breast"],"interventions":[{"type":"DRUG","name":"Lapatinib","otherNames":[]},{"type":"DRUG","name":"Trastuzumab","otherNames":[]},{"type":"DRUG","name":"Aromatase Inhibitor","otherNames":[]},{"type":"DRUG","name":"Lapatinib","otherNames":[]}],"arms":[{"label":"Treatment group A","type":"EXPERIMENTAL"},{"label":"Treatment group B","type":"ACTIVE_COMPARATOR"},{"label":"Treatment Group C","type":"ACTIVE_COMPARATOR"}],"summary":"A study to compare the safety and efficacy of an aromatase inhibitor in combination with lapatinib, trastuzumab or both for the treatment of hormone receptor positive, HER2+ metastatic breast cancer (MBC).","primaryOutcome":{"measure":"Progression Free Survival (PFS) Events in Lapatinib + Trastuzumab + Aromatase Inhibitor (AI) vs. Trastuzumab + Aromatase Inhibitor (AI)","timeFrame":"From date of randomization until date of progression or date of death from any cause, whichever comes first, assessed up approximately 5 years","effectByArm":[{"arm":"Lapatinib + Trastuzumab + Aromatase Inhibitor (AI)","deltaMin":62,"sd":null},{"arm":"Trastuzumab + Aromatase Inhibitor (AI)","deltaMin":75,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":"0.0063"}]},"eligibility":{"minAge":"18 Years","sex":"FEMALE","healthyVolunteers":false,"inclusionCount":2,"exclusionCount":null},"locations":{"siteCount":110,"countries":["United States","Argentina","Australia","Belgium","Brazil","Bulgaria","China","Croatia","France","Germany","Greece","Hong Kong","Hungary","India","Israel","Italy","Japan","Peru","Poland","Portugal","Russia","Serbia","Singapore","South Korea","Spain","Taiwan","Turkey (TÃ¼rkiye)","Ukraine","United Kingdom"]},"refs":{"pmids":["29244528","32822287"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":27,"n":123},"commonTop":["Diarrhoea","Rash","Nausea","Paronychia","Arthralgia"]}}